GO StudiO

Many women suffer from hyperandrogenic conditions during their lifespan. The most prevalent is polycystic ovary syndrome (PCOS), which is characterized by hormonal, metabolic, and reproductive derangements in women of reproductive age. Endometrial cancer of epithelial origin (EC) is among the most common malignancies affecting women’s reproductive systems. It has been suggested that androgens are...

The provided text outlines a comprehensive expert recommendation and roadmap for the future of high-grade serous carcinoma (HGSC) research and treatment. Drawing from the 15th Helene Harris Memorial Trust International Forum, the document synthesizes a decade of progress while identifying critical gaps in early detection and acquired resistance. It highlights the shift toward recognizing the Fallo...

This study investigates the prevalence of undetected malignant nodules during surgery for colorectal and ovarian cancer that has spread to the peritoneum. Researchers conducted a prospective trial where a second senior surgeon performed an immediate re-evaluation of the abdomen after the primary surgeon deemed the cancer removal complete. The findings revealed that nearly half of the patients stil...

Drugging the undruggable through novel synthetic lethal strategies This session highlights how leveraging synthetic lethality is opening new therapeutic avenues for targets once considered beyond reach. A promising step forward in precision oncology and the development of more effective, mechanism-driven treatments. Speaker Timothy Anthony Yap

The addition of bevacizumab to chemotherapy has been shown to improve progression-free survival (PFS) in patients with ovarian cancer, with the greatest benefit observed in those with high-risk disease, and the combination of bevacizumab and olaparib has been approved as a first-line maintenance treatment for patients with homologous recombination deficiency (HRD)-positive advanced ovarian cancer....

This episode explores the growing role of antibody–drug conjugates (ADCs) in the treatment of ovarian cancer. ADCs combine a targeted monoclonal antibody with a cytotoxic drug, allowing chemotherapy to be delivered directly to tumor cells while limiting damage to healthy tissue. The discussion highlights two currently approved ADCs in ovarian cancer: mirvetuximab soravtansine, used for platinum-re...